The Datar Cancer Genetics Medical Ceer in Maharashtra, India, has iroduced an artificial ielligence platform called the Exacta AI, which offers the most optimized treatme options for cancer paties with multi -elevated analytics.
The platform combines molecular, proteumic, genomic, functional and clinical data and proposes personalized therapeutic solutions using artificial ielligence. Also Exacta AI also provides drug ieractions, toxicity and coraindications for a wide range of therapies; Such as aibody combined drugs (ADCS), the inhibitors of immune corol stations (CPIS), targeted therapies, hormone therapy, chemotherapy and recovered drugs.
The system can offer up to 10 evidence -based drug compounds for oncologists and molecular tumors (MTBS).
“This approach based on artificial ielligence offers an iegrated and evidence -based set of treatme options that can customize cancer treatme,” says Dr. Swai Lima, director of the Sir Hn Relision Foundation Hospital. To transform it. “
Also, Dr. Dar Dary Patiel, chief executive of World Strategy and Medical Affairs at DCG, pois to the platform’s capability to process a huge volume of clinical and molecular data, saying: “When standard treatmes are not responsive, physicians must have a large volume of data. Check out and make critical decisions in the shortest possible time. “Exacta AI makes this challenge an opportunity to provide personalized therapies.”
This system based on artificial ielligence also improves the workflow of molecular tumor (MTB) and structured analysis provides physicians with evidence -based treatme options.
The Exacta AI platform offered at least seven treatme options for each patie in a review study of four paties with drug -resista cancers in hard organs (such as lungs, liver or breast). In corast, the usual molecular survey methods offered only two options for 2 % of paties.
Dr. Vinnite Data, chief executive of the World Strategy and Business Developme in DCG, described the technology as a virtual multidisciplinary team that processs data in minutes, while the process takes several days in traditional methods.
The Exacta AI is now available for medical ceers and hospitals and comes with training, iegration and coinuous support.
“This technology provides an unprecedeed level and can protect them from being exposed to ineffective treatmes,” says Dr. Andy Gaya, an oncology expert at The Cromwell London Hospital.
The 4basecare startup, backed by Infosys, has also provided a similar approach to treat cancer paties in India.
Hitash Gousami, a co -founder and CEO of 4basecare, explained that today the lung cancer paties are divided io differe groups in steps 1 and 2 to 2, each group needs its own treatme. A treatme that is effective for one group may not be effective for the other group and even cause side effects.
This shows that the future of cancer treatme will move to fully personalized treatmes, instead of standard and uniform methods for all paties.
